Jove
Visualize
Contact Us
JoVE
x logofacebook logolinkedin logoyoutube logo
ABOUT JoVE
OverviewLeadershipBlogJoVE Help Center
AUTHORS
Publishing ProcessEditorial BoardScope & PoliciesPeer ReviewFAQSubmit
LIBRARIANS
TestimonialsSubscriptionsAccessResourcesLibrary Advisory BoardFAQ
RESEARCH
JoVE JournalMethods CollectionsJoVE Encyclopedia of ExperimentsArchive
EDUCATION
JoVE CoreJoVE BusinessJoVE Science EducationJoVE Lab ManualFaculty Resource CenterFaculty Site
Terms & Conditions of Use
Privacy Policy
Policies

Filters

E Arrowsmith

Showing results (71-80 of 72) with videos related to

Pageof 8
Sort By:
You have reached the last page of results.This site can display upto 72 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
The Heart Surgery Forum|May 7, 2010
Consensus statement: minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypassR Clive Landis, John M Murkin, David A Stump, et al.
Pageof 8

Showing results (71-80 of 72) with videos related to

Sort By:
Pageof 8
You have reached the last page of results.This site can display upto 72 results.
Annals of Oncology : Official Journal of the European Society for Medical Oncology|October 22, 2016
Ramucirumab combined with FOLFOX as front-line therapy for advanced esophageal, gastroesophageal junction, or gastric adenocarcinoma: a randomized, double-blind, multicenter Phase II trialH H Yoon, J C Bendell, F S Braiteh, et al.
The Heart Surgery Forum|May 7, 2010
Consensus statement: minimal criteria for reporting the systemic inflammatory response to cardiopulmonary bypassR Clive Landis, John M Murkin, David A Stump, et al.
Pageof 8